脂肪性肝炎-话题@MedSci

#脂肪性肝炎#

121篇内容 | 3325人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1956091, encodeId=74f8195609136, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=诺和诺德的GLP-1激动剂semaglutide：非酒精性脂肪性肝炎的II期临床展现治疗潜力, objectType=article, longId=193810, objectId=97c7193810df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97c7193810df, replyNumber=0, likeNumber=55, createdTime=2020-07-12, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97c7193810df, moduleTitle=诺和诺德的GLP-1激动剂semaglutide：非酒精性脂肪性肝炎的II期临床展现治疗潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97c7193810df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956071, encodeId=e60e19560e154, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=Terns宣布其血管粘附蛋白-1抑制剂TERN-201治疗非酒精性脂肪性肝炎的I期临床中期阳性结果, objectType=article, longId=177617, objectId=12b31e761746, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12b31e761746, replyNumber=0, likeNumber=50, createdTime=2020-03-24, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12b31e761746, moduleTitle=Terns宣布其血管粘附蛋白-1抑制剂TERN-201治疗非酒精性脂肪性肝炎的I期临床中期阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12b31e761746)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956069, encodeId=3574195606914, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=Clinica Chimica Acta：非酒精性脂肪性肝炎患者血清脂蛋白中缩醛磷脂的组成及其对氧化作用的敏感性, objectType=article, longId=177031, objectId=14cb1e703109, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14cb1e703109, replyNumber=0, likeNumber=0, createdTime=2020-01-15, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14cb1e703109, moduleTitle=Clinica Chimica Acta：非酒精性脂肪性肝炎患者血清脂蛋白中缩醛磷脂的组成及其对氧化作用的敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14cb1e703109)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956075, encodeId=185619560e524, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=AASLD年会：新科技！新型机器学习模型可有效预测非酒精性脂肪性肝炎（NASH）发生, objectType=article, longId=183523, objectId=1d061835231a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d061835231a, replyNumber=0, likeNumber=121, createdTime=2020-07-05, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d061835231a, moduleTitle=AASLD年会：新科技！新型机器学习模型可有效预测非酒精性脂肪性肝炎（NASH）发生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d061835231a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956089, encodeId=581a1956089a4, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=A3腺苷受体激动剂Namodenoson，治疗非酒精性脂肪性肝炎（NASH）的II期研究成功, objectType=article, longId=191736, objectId=e771191e364a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e771191e364a, replyNumber=0, likeNumber=74, createdTime=2021-03-17, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e771191e364a, moduleTitle=A3腺苷受体激动剂Namodenoson，治疗非酒精性脂肪性肝炎（NASH）的II期研究成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e771191e364a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956072, encodeId=80a019560e2d9, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=非酒精性脂肪性肝炎（NASH）的治疗：ASC40获得中国NMPA的IND, objectType=article, longId=178354, objectId=2b001e835408, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b001e835408, replyNumber=0, likeNumber=87, createdTime=2020-08-08, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b001e835408, moduleTitle=非酒精性脂肪性肝炎（NASH）的治疗：ASC40获得中国NMPA的IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b001e835408)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956076, encodeId=e9e219560e672, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=Lancet：奥贝胆酸治疗非酒精性脂肪性肝炎III期临床获得成功, objectType=article, longId=184494, objectId=2df618449455, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2df618449455, replyNumber=0, likeNumber=65, createdTime=2020-03-23, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2df618449455, moduleTitle=Lancet：奥贝胆酸治疗非酒精性脂肪性肝炎III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2df618449455)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956070, encodeId=f7a919560e0b7, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=AP&T：长期使用二甲双胍可改善糖尿病患者的非酒精性脂肪性肝炎和肝硬化的临床预后, objectType=article, longId=177409, objectId=01b81e7409e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01b81e7409e2, replyNumber=0, likeNumber=58, createdTime=2020-02-26, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01b81e7409e2, moduleTitle=AP&T：长期使用二甲双胍可改善糖尿病患者的非酒精性脂肪性肝炎和肝硬化的临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01b81e7409e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956077, encodeId=35f919560e7e1, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=J hepatology：奥贝胆酸对非酒精性脂肪性肝炎患者脂蛋白谱的影响, objectType=article, longId=185404, objectId=6f5918540456, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f5918540456, replyNumber=0, likeNumber=79, createdTime=2020-11-12, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f5918540456, moduleTitle=J hepatology：奥贝胆酸对非酒精性脂肪性肝炎患者脂蛋白谱的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f5918540456)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956073, encodeId=778519560e3e7, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=Enanta宣布其FXR激动剂EDP-305治疗非酒精性脂肪性肝炎的临床研究积极成果, objectType=article, longId=180093, objectId=cf0518009397, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf0518009397, replyNumber=0, likeNumber=76, createdTime=2020-09-02, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf0518009397, moduleTitle=Enanta宣布其FXR激动剂EDP-305治疗非酒精性脂肪性肝炎的临床研究积极成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf0518009397)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956061, encodeId=51d519560619d, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=Intercept公司的奥贝胆酸即将成为第一个获批的非酒精性脂肪性肝炎（NASH）药物, objectType=article, longId=160664, objectId=b09616066462, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b09616066462, replyNumber=0, likeNumber=57, createdTime=2019-10-13, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b09616066462, moduleTitle=Intercept公司的奥贝胆酸即将成为第一个获批的非酒精性脂肪性肝炎（NASH）药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b09616066462)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956063, encodeId=082c1956063c3, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=J Gastroenterology：利用外周血中单个核细胞基因表达水平进行非酒精性脂肪性肝炎的无创诊断, objectType=article, longId=161800, objectId=4d3e161800f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d3e161800f8, replyNumber=0, likeNumber=64, createdTime=2019-04-11, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d3e161800f8, moduleTitle=J Gastroenterology：利用外周血中单个核细胞基因表达水平进行非酒精性脂肪性肝炎的无创诊断, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d3e161800f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956066, encodeId=118a195606653, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=非酒精性脂肪性肝炎：cilofexor/firsocostat组合在概念验证研究中改善了NASH症状, objectType=article, longId=164168, objectId=8b68164168af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b68164168af, replyNumber=0, likeNumber=46, createdTime=2019-11-04, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b68164168af, moduleTitle=非酒精性脂肪性肝炎：cilofexor/firsocostat组合在概念验证研究中改善了NASH症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b68164168af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956057, encodeId=b27c195605e4b, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=Cell Rep：揭示非酒精性脂肪性肝炎发病免疫机制, objectType=article, longId=157983, objectId=e76315e983e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e76315e983e5, replyNumber=0, likeNumber=55, createdTime=2019-12-19, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e76315e983e5, moduleTitle=Cell Rep：揭示非酒精性脂肪性肝炎发病免疫机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e76315e983e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956068, encodeId=de6c19560689b, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=Boehringer Ingelheim与韩国Yuhan签订8.7亿美元合同，合作开发非酒精性脂肪性肝炎的双重激动剂, objectType=article, longId=174741, objectId=97ed1e4741da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97ed1e4741da, replyNumber=0, likeNumber=97, createdTime=2020-04-09, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97ed1e4741da, moduleTitle=Boehringer Ingelheim与韩国Yuhan签订8.7亿美元合同，合作开发非酒精性脂肪性肝炎的双重激动剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97ed1e4741da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956067, encodeId=5a82195606e77, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=GENFIT宣布DSMB的积极建议，将继续进行Elafibranor治疗非酒精性脂肪性肝炎的3期临床研究, objectType=article, longId=166113, objectId=36251661133d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36251661133d, replyNumber=0, likeNumber=56, createdTime=2019-11-16, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36251661133d, moduleTitle=GENFIT宣布DSMB的积极建议，将继续进行Elafibranor治疗非酒精性脂肪性肝炎的3期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36251661133d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956059, encodeId=c67a195605908, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=Hepatology：丁酸钠可以通过上调肝脏GLP-1R表达减少高脂饮食诱导的非酒精性脂肪性肝炎, objectType=article, longId=158523, objectId=8bfb158523b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8bfb158523b9, replyNumber=0, likeNumber=56, createdTime=2019-06-11, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8bfb158523b9, moduleTitle=Hepatology：丁酸钠可以通过上调肝脏GLP-1R表达减少高脂饮食诱导的非酒精性脂肪性肝炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8bfb158523b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956064, encodeId=d9ae1956064c1, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=Clinical Gastroenterology H：非酒精性脂肪性肝炎是等待肝移植患者中肝癌发生原因中上升最快的病因, objectType=article, longId=161860, objectId=25991618607e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25991618607e, replyNumber=0, likeNumber=52, createdTime=2019-10-15, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25991618607e, moduleTitle=Clinical Gastroenterology H：非酒精性脂肪性肝炎是等待肝移植患者中肝癌发生原因中上升最快的病因, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25991618607e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956062, encodeId=c27d195606290, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=2019 共识指南：非酒精性脂肪性肝炎患者临床试验期间疑似急性药物性肝损伤的检测、评估和管理实践, objectType=article, longId=161354, objectId=39bc161354db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39bc161354db, replyNumber=0, likeNumber=89, createdTime=2019-08-15, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39bc161354db, moduleTitle=2019 共识指南：非酒精性脂肪性肝炎患者临床试验期间疑似急性药物性肝损伤的检测、评估和管理实践, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39bc161354db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956065, encodeId=b3531956065de, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=PLOS ONE：西方饮食诱导的非酒精性脂肪性肝炎的脂质组学和转录组学分析, objectType=article, longId=163707, objectId=9b6f163e0771, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b6f163e0771, replyNumber=0, likeNumber=57, createdTime=2019-04-28, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b6f163e0771, moduleTitle=PLOS ONE：西方饮食诱导的非酒精性脂肪性肝炎的脂质组学和转录组学分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b6f163e0771)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

脂肪性肝炎

2020-05-29

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

诺和诺德的GLP-1激动剂semaglutide：非酒精性脂肪性肝炎的II期临床展现治疗潜力

2020-07-12

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

Terns宣布其血管粘附蛋白-1抑制剂TERN-201治疗非酒精性脂肪性肝炎的I期临床中期阳性结果

2020-03-24

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

Clinica Chimica Acta：非酒精性脂肪性肝炎患者血清脂蛋白中缩醛磷脂的组成及其对氧化作用的敏感性

2020-01-15

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

AASLD年会：新科技！新型机器学习模型可有效预测非酒精性脂肪性肝炎（NASH）发生

2020-07-05

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

A3腺苷受体激动剂Namodenoson，治疗非酒精性脂肪性肝炎（NASH）的II期研究成功

2021-03-17

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

非酒精性脂肪性肝炎（NASH）的治疗：ASC40获得中国NMPA的IND

2020-08-08

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

Lancet：奥贝胆酸治疗非酒精性脂肪性肝炎III期临床获得成功

2020-03-23

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

AP&T：长期使用二甲双胍可改善糖尿病患者的非酒精性脂肪性肝炎和肝硬化的临床预后

2020-02-26

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

J hepatology：奥贝胆酸对非酒精性脂肪性肝炎患者脂蛋白谱的影响

2020-11-12

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

Enanta宣布其FXR激动剂EDP-305治疗非酒精性脂肪性肝炎的临床研究积极成果

2020-09-02

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

Intercept公司的奥贝胆酸即将成为第一个获批的非酒精性脂肪性肝炎（NASH）药物

2019-10-13

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

J Gastroenterology：利用外周血中单个核细胞基因表达水平进行非酒精性脂肪性肝炎的无创诊断

2019-04-11

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

非酒精性脂肪性肝炎：cilofexor/firsocostat组合在概念验证研究中改善了NASH症状

2019-11-04

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

Cell Rep：揭示非酒精性脂肪性肝炎发病免疫机制

2019-12-19

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

Boehringer Ingelheim与韩国Yuhan签订8.7亿美元合同，合作开发非酒精性脂肪性肝炎的双重激动剂

2020-04-09

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

GENFIT宣布DSMB的积极建议，将继续进行Elafibranor治疗非酒精性脂肪性肝炎的3期临床研究

2019-11-16

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

Hepatology：丁酸钠可以通过上调肝脏GLP-1R表达减少高脂饮食诱导的非酒精性脂肪性肝炎

2019-06-11

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

Clinical Gastroenterology H：非酒精性脂肪性肝炎是等待肝移植患者中肝癌发生原因中上升最快的病因

2019-10-15

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

2019 共识指南：非酒精性脂肪性肝炎患者临床试验期间疑似急性药物性肝损伤的检测、评估和管理实践

2019-08-15

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

PLOS ONE：西方饮食诱导的非酒精性脂肪性肝炎的脂质组学和转录组学分析

2019-04-28

科室
- - 订阅+
  - 更多科室
工具
服务